Product category:
Nucleic acid sequencing and synthesis
News Release from: Applied Biosystems | Subject: MicroRNAs
Edited by the Laboratorytalk Editorial
Team on 09 June 2006
MicroRNA assay choice grows
Applied Biosystems has expanded its range of TaqMan MicroRNA Assays, now offering nearly 300 individual assays for cell differentiation, developmental biology, stem cell and cancer research
The assays are based on a simple two-step process using Applied Biosystems's proprietary stem-loop technology for reverse transcription (RT) of the mature microRNA followed by quantitative real-time PCR In preliminary studies, the assays were able to quantify microRNAs in samples as small as 25picograms of total RNA and discriminate between highly homologous mature microRNAs, such as the hsa-let-7 family
This article was originally published on Laboratorytalk on 3 Jul 2007 at 8.00am (UK)
Related stories
New role for microRNAs in stopping tumour growth
In this study, researchers performed extensive gene expression profiling experiments that identified three miRNA genes called miR-34s as candidate tumour suppressor genes
These assays are able to discriminate between highly homologous microRNAs, and the precursor and mature microRNAs.
This specificity, combined with the sensitivity and dynamic range of gold-standard TaqMan assay chemistry and real-time PCR, offers a robust, easily scalable, and cost effective method to relate the expression of microRNAs with cell types.
"We have been using the TaqMan MicroRNA Assays to study different types of brain tumours," said Prof Victor Ambros of Dartmouth Medical School, New Hampshire, and the original discoverer of microRNA molecules.
"Our studies show these assays to be the most reliable and quantitative way to screen for microRNA biomarkers that distinguish tumour types.".
• Applied Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
